Roadmap for Using Convalescent Plasma Against COVID-19
A new analysis shows how convalescent plasma can be used to prevent hospitalizations and ultimately save lives, both for COVID-19 and for the next viral pandemic that inevitably arrives.
Tag: convalescent plasma
All
Latest
Roadmap for Using Convalescent Plasma Against COVID-19
A new analysis shows how convalescent plasma can be used to prevent hospitalizations and ultimately save lives, both for COVID-19 and for the next viral pandemic that inevitably arrives.
Read More
COVID Convalescent Plasma an Effective Early Therapy
COVID convalescent plasma from recovered patients whose blood contains antibodies against SARS-CoV-2 is an effective and safe option as an early outpatient treatment, according to NEJM research.
Read More
Study: No Safety Concerns for Convalescent Plasma Treatment for High-risk Children
A study of 14 children at Johns Hopkins Children’s Center found convalescent plasma provided expected antibody levels and raised no safety concerns in high-risk children infected with or exposed to SARS-CoV-2.
Read More
Convalescent Plasma Cut Hospitalizations in Half
Convalescent plasma reduced the need for hospitalization by half for outpatients with COVID-19, according to a nationwide, multicenter clinical trial led by Johns Hopkins Medicine.
Read More
NIH Expanding Convalescent Plasma Clinical Trials
Two randomized, placebo-controlled clinical trials funded by the NIH are expanding enrollment to further evaluate convalescent plasma for COVID-19.
Read More
FDA Authorizes Convalescent Plasma for COVID-19
Convalescent plasma may be effective in lessening the severity or shortening the length of COVID-19 illness in some hospitalized patients, the FDA said.
Read More
FDA Updates Guidance on Convalescent Plasma
The US FDA has updated its guidance on COVID-19 convalescent plasma to amend requirements for potential donors and to provide clarification on how researchers may submit investigational applications.
Read More
FDA Expanding Access to Blood-related Therapies for COVID-19
The FDA is expanding access and development for two investigational blood-based therapies for COVID-19—convalescent plasma and hyperimmune globulin.
Read More